2004
DOI: 10.1002/ijc.11712
|View full text |Cite
|
Sign up to set email alerts
|

Survival after adjuvant 5‐FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
63
0
1

Year Published

2005
2005
2012
2012

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 90 publications
(64 citation statements)
references
References 18 publications
0
63
0
1
Order By: Relevance
“…Our previous studies and the studies of others (79)(80)(81)(82) demonstrated that MSI tumors respond poorly to 5-fluorouracil (5-FU) therapy, and alternative chemotherapeutic regimens for patients with MSI tumors are needed to improve overall survival. Interestingly, cancer cell lines with low CHFR expression exhibit heightened susceptibility to the microtubule destabilizers (25,27).…”
Section: Discussionmentioning
confidence: 99%
“…Our previous studies and the studies of others (79)(80)(81)(82) demonstrated that MSI tumors respond poorly to 5-fluorouracil (5-FU) therapy, and alternative chemotherapeutic regimens for patients with MSI tumors are needed to improve overall survival. Interestingly, cancer cell lines with low CHFR expression exhibit heightened susceptibility to the microtubule destabilizers (25,27).…”
Section: Discussionmentioning
confidence: 99%
“…However, there are conflicting reports on the relation between MSI status and outcome of fluorouracil-based adjuvant chemotherapy. Some authors report that stage III MSI cancers derive the greatest benefit (Elsaleh et al, 2000), others that MSI status is not predicting response (de Vos tot Nederveen Cappel et al, 2004). These studies have recently been challenged by a large study showing that only MSS patients derived a benefit from the treatment (Brezden-Masley et al, 2003).…”
Section: Discussionmentioning
confidence: 99%
“…It is shown that MSI+ patients are less responsive to the fluorouracil than those who are MSI-. Thus, fluorouracil adjuvant chemotherapy shows not only no benefit in MSI+ patients but may also decrease the survival of these patients (24).…”
Section: Discussionmentioning
confidence: 99%